Trials / Completed
CompletedNCT02517892
A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,500 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective study to identify molecular mechanisms of acquired resistance to targeted therapies in patients with unresectable or metastatic cancer. This is a protocol to study clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The tissues and other specimens will be used to carry out laboratory studies to explore the molecular basis of acquired resistance to targeted therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Biopsy |
Timeline
- Start date
- 2014-12-18
- Primary completion
- 2025-03-01
- Completion
- 2025-03-01
- First posted
- 2015-08-07
- Last updated
- 2025-06-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02517892. Inclusion in this directory is not an endorsement.